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ABSTRACT
Background. Neoadjuvant chemoradiotherapy (CRT)
followed by radical surgery including total mesorectal
excision (TME) is standard treatment in patients with
locally advanced rectal cancer. Emerging data indicate that
patients with complete pathologic response (ypCR) after
CRT have favorable outcome, suggesting the possibility of
less invasive surgical treatment. We analyzed long-term
outcome of cT3 rectal cancer treated by neoadjuvant CRT
in relation to ypCR and type of surgery.
Methods. The study population comprised 139 patients
(93 men, 46 women; median age 62 years) with cT3N0–
1M0 mid and distal rectal adenocarcinoma treated by CRT
and surgery (110 TME and 29 local excision) at our
institution between 1996 and 2008. At pathology, ypCR
was deﬁned as no residual cancer cells in the primary
tumor.
Results. Tumors of 42 patients (30.2%) were classiﬁed as
ypCR. After a median follow-upof 55.4 months, comparing
patientswithypCRtopatientswithnoypCR,5-yeardisease-
speciﬁc survival was 95.8% versus 78.0% (P = 0.004), and
5-year disease-free survival was 90.1% vs. 64.0%
(P = 0.004). In patients with ypCR, no statistically signiﬁ-
cant outcome difference was observed between TME and
local excision. In patients treated by local excision, com-
paring patients with ypCR to patients with no ypCR, 5-year
disease-free survival was 100% vs. 65.5% (P = 0.024), and
5-year local recurrence-free survival was 92.9% vs. 66.7%
(P = 0.047).
Conclusions. With retrospective analysis limitations, our
data conﬁrm favorable long-term outcome of cT3 rectal
cancer with ypCR after CRT and warrant clinical trials
exploring local excision surgical strategies.
Neoadjuvant chemoradiotherapy (CRT) followed by
radical surgery including total mesorectal excision (TME)
has been shown to effectively improve local control and is
the recommended treatment in patients with locally
advanced (T3–4 or any N1–2) mid–distal rectal cancer.
1–5
Tumor regression after CRT is observed in most of the
patients, and an absence of residual neoplasia in the
resected specimen, known as complete pathologic response
(ypCR), has been reported in up to one-third of cases, with
its incidence largely varying among different studies.
6
Accumulating evidences indicate that patients with
locally advanced rectal cancer showing ypCR after CRT
have more favorable long-term outcome compared to
patients with less degree or no pathologic response.
7–12
Moreover, tumor regression after neoadjuvant CRT may be
observed not only in the primary tumor but also in meso-
rectal metastatic lymph nodes.
13–18 In view of these data,
along with the available information on outcome of locally
advanced rectal cancer treated by local excision (LE),
organ-preserving strategies have been considered for the
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19–26 In addition,
given the encouraging long-term results of a nonoperative
treatment in patients with complete clinical response to
CRT, a watch-and-wait policy has been also advo-
cated.
27–29 The decision making of optimal treatment for
patients with locally advanced rectal cancer is a crucial
issue because the risk of surgery-related morbidity, mor-
tality, and quality of life has to be balanced with the risk of
local and distal recurrence. Therefore, data on the long-
term outcome in relation to the grade of pathologic
response and to the type of surgical treatment in patients
with locally advanced rectal cancer treated by neoadjuvant
CRT are greatly needed.
Because patients with clinical T3 (cT3) rectal cancer
showing ypCR after neoadjuvant CRT represent the
potential target population for a conservative surgical
approach including organ preservation, the aim of this
study was to analyze the long-term outcome in a subset of
such patients, which also included a number of patients
who underwent full-thickness LE, treated at our institution
during a 12-year period.
METHODS
All consecutive patients treated by neoadjuvant CRT
and surgery for cT3 rectal cancer between January 1996
and September 2008 were identiﬁed from our institutional,
prospectively maintained rectal cancer database. Patients
with synchronous distant metastasis were excluded from
the study. All patients had biopsy-proven adenocarcinoma
of the rectum. The distance of the tumor from the anal
verge was measured by rigid rectoscopy. Pre- and post-
CRT primary tumor and nodal staging were evaluated by
endorectal ultrasound and/or pelvic magnetic resonance
imaging. Lymph nodes C 5 mm in size were considered
positive. In cases with discrepancy between the two
imaging techniques the higher stage was considered. Dis-
tant metastasis was excluded by thoracoabdominal and
pelvic computed tomographic scan.
Preoperative CRT
Preoperative CRT was provided according to several
preoperative sequential treatment protocols developed at
our institute between 1994 and 2008, including 5-ﬂuoro-
uracil (5-FU) bolus with leucovorin and 45 Gy with or
without adjuvant 5-FU/leucovorin, raltitrexed, and 50.4 Gy
plus 10 Gy intraoperative radiotherapy (IORT), capecita-
bine, and 50.4 Gy, continuous infusion (c.i.) 5-FU with
geﬁtinib and 50.4 Gy plus 10 Gy IORT, and capecitabine
with or without oxaliplatin and 50.4 Gy (ongoing
study).
30–33 The radiotherapy (RT) clinical target volume
(CTV2) included the primary tumor, the mesorectum, and
the internal iliac lymph nodes. A second CTV1 included
the mesorectum corresponding to the primary tumor with
2-cm radial margin. RT fractionation was of 180 cGy/day,
5 fractions per week. More details on the RT technique
have been previously reported.
32
Surgery
Patients underwent surgery 6–8 weeks after completion
of neoadjuvant CRT. Surgical procedures included
abdominoperineal resection (APR), low anterior resection
(LAR), and full-thickness transanal LE. Radical resection
was performed according to TME principles. Reasons for
the use of LE included patient refusal of APR, medical
comorbidity, and patient preference after a major (com-
plete) clinical response. Toward the last study period,
patients with disease with major response to CRT, even if
they did not absolutely refuse APR, were offered the option
of LE after appropriate informed consent. IORT to high-
risk area (presacral region) was provided after surgical
resection, according to the study protocols mentioned
above.
Postoperative Chemotherapy
Adjuvant 5-FU-based chemotherapy was provided
according to study protocol, or in selected cases including
patients with metastatic lymph nodes.
Pathology
Pathologic tumor staging was performed according to
the guidelines of the American Joint Committee on Cancer
and College of American Pathologists.
34 Histopathologic
examination of the surgical specimens was performed by
gastrointestinal experienced pathologists by using a stan-
dardized protocol according to Quirke and Dixon.
35 Cases
with no residual cancer cells in the surgical specimen were
considered pathologic complete responders (ypCR/ypT0).
Mucous lakes without identiﬁable carcinoma cells were not
considered as residual tumor.
Follow-up
Postoperatively, patients were examined at follow-up
visits every 3 months for the ﬁrst 2 years and every
6 months thereafter. At each follow-up control, carcino-
embryonic antigen level was determined. Abdominal and
pelvic computed tomographic scan or liver ultrasound and
chest x-ray were performed alternately every 3–6 months.
Colonoscopy was performed yearly. All patients were
Long-Term Outcome of T3 Rectal Cancer with ypCR 3687followed up at a dedicated outpatient multidisciplinary
clinic.
Statistical Analysis
Chi-square test or Fisher’s exact test were used to
compare percentages between disease that responded
completely and disease that did not respond completely,
and the Wilcoxon rank test was performed for median age
comparison. Cumulative probabilities of overall survival
(OS), disease-speciﬁc survival (DSS), disease-free survival
(DFS), distant metastasis–free survival (DMFS), and local
recurrence-free survival (LRFS) were estimated by Kaplan-
Meier survival methods, and differences between sub-
groups were assessed by the log rank test.
36 Duration of
follow-up was calculated as the time from surgery to the
event of interest. Patients without event were censored at
the date of last follow-up. In cases of local and distant
metastasis, both events were recorded and computed at any
time of occurrence. To better assess the oncologic impli-
cations of ypCR, the Cox proportional hazards model was
used for adjusting the hazard ratios and corresponding 95%
conﬁdence intervals.
37 Because of the limitation of sample
size and number of events, only three variables were
entered in the multivariate model: cN stage (cN0 vs. cN1),
type of surgery (TME vs. LE), and ypCR (yes vs. no). A P
value of B 0.05 was considered statistically signiﬁcant
(two tailed). SAS software, version 9.2 (SAS Institute,
Cary, NC), was used to perform the data analysis.
RESULTS
A total of 188 consecutive patients with rectal adeno-
carcinoma treated by neoadjuvant CRT followed by
surgery with TME (LAR and APR) or LE at our institution
between January 1996 and September 2008 were identiﬁed.
Initially considered for this study were 150 cT3 rectal
cancer patients. Of these, 11 were excluded because they
had synchronous distant metastasis, leaving a total of 139
patients for analysis. Complete pathologic response in the
primary tumor was observed in 42 patients (30%).
Patients and Treatment Characteristics
There were 93 male (67%) and 46 female (33%)
patients. The median age was 62 years (range, 25–
87 years). Seventy-two patients had disease staged as
cT3N0 (52%) and 67 as cT3N1 (48%). Median distance of
the tumor from the anal verge was 5 cm (range, 1–12 cm).
Total RT dose was 45 Gy in 41 patients (29%) and 50.4 Gy
in 98 patients (71%). TME surgery was performed in 110
patients (83%) (92 LAR, 18 APR), while LE was
performed in 29 patients (17%). Documented reasons for
the use of LE were preference after a major clinical
response in 22 cases, patient absolute refusal of APR in 4
cases, and medical comorbidity in 3 cases. In 41 patients
(29%), IORT was applied in the context of clinical studies.
Postoperative chemotherapy was administered in 39
patients (28%).
Clinical and Pathologic Response
Clinical restaging before surgery demonstrated primary
tumor downstaging (deﬁned as ycT B 2) in 96 patients
(69%), 15 of whom (11%) had disease that was restaged as
ycT0. Pathologic tumor staging was ypT0 in 42 patients
(30%), ypT1 in 11 (8%), ypT2 in 45 (32%), and ypT3 in 41
(30%). Therefore, ypCR was achieved in 30% of the
patients. Among the 15 ycT0 tumors, 11 (73%) were found
to be ypT0, 2 ypT1, and 2 ypT2. Pathology information
about lymph node metastatic status were available in all the
110 patients treated by TME surgery. The median number
of lymph nodes examined was 14 (range, 2–32). Metastatic
lymph nodes were identiﬁed in 27 patients (25%) (19
ypN1, and 8 ypN2). All patients with disease initially
staged as cN0 resulted in ypN0 disease. Metastatic lymph
nodes were found in 3 (all cN positive) of 25 ypCR patients
(12%), and in 24 (29%) of 85 no-ypCR patients (P = NS).
In the 60 patients with disease initially staged as cN
positive, no metastatic lymph nodes were identiﬁed in 12
(80%) of 15 ypCR patients, and in 21 (47%) of 45 no-ypCR
patients (P = 0.055). Table 1 outlines the distribution of
clinicopathologic and treatment characteristics according
to ypCR. There were no statistically signiﬁcant clinico-
pathologic differences in ypCR patients compared to no-
ypCR patients, while TME surgery, IORT, and adjuvant
chemotherapy were used signiﬁcantly more in the group of
no-ypCR patients. Clinicopathologic and treatment char-
acteristics according to the type of surgery in the 42 ypCR
patients are reported in Table 2.
Recurrence and Survival
There was no postoperative mortality. During a median
follow-up of 55.4 months, 12 patients (8.6%) developed
local recurrence only, 9 (6.5%) developed local recurrence
and distant metastasis (7 liver and 2 lung), and 18 (12.9%)
distant metastasis only (9 liver, 4 lung, 4 liver and lung,
and 1 lung and brain). In the entire patient population, OS,
DSS, DFS, DMFS, and LRFS were 79.1, 83.4, 72.2, 80.5,
and 84.3%, respectively. In the subset of 42 patients with
ypCR, 1 patient (2.4%) developed local recurrence only, 1
patient (2.4%) local recurrence and liver metastasis, and 3
patients (7.1%) distant metastasis only (1 liver, and 2 liver
and lung). Comparing patients with ypCR (n = 42) to
3688 C. Belluco et al.patients with no ypCR (n = 97), the 5-year OS was 89.5%
versus 74.7%, respectively (P = 0.026), the 5-year DSS
was 95.8% versus 78.0% (P = 0.004), the 5-year DFS was
90.1% versus 64.0% (P = 0.004), the 5-year DMFS was
92.5% versus 74.9% (P = 0.038), and the 5-year LRFS
was 94.9% versus 79.6% (P = 0.023) (Fig. 1). In ypCR
patients, no statistically signiﬁcant differences were
observed in any of the outcome end points comparing
patients treated by surgery including TME and patients
treated by LE (Fig. 2). In the subset of 29 patients treated
by CRT followed by LE, comparing patients with ypCR
(n = 17) to patients with no ypCR (n = 12), the 5-year OS
was 92.3% versus 65.5%, respectively (P = NS), the
5-year DSS was 100% versus 65.5% (P = 0.024), the
5-year DFS was 87.4% versus 58.3% (P = NS), the 5-year
DMFS was 87.4% versus 69.4% (P = NS), and the 5-year
LRFS was 92.9% versus 66.7 (P = 0.047) (Fig. 3).
At multivariate analysis, ypCR was a signiﬁcant prog-
nostic factor for OS, DSS, DFS, DMFS, and LRFS,
independent from cN stage and type of surgery (Table 3).
DISCUSSION
In the present study, we evaluated the oncologic out-
come of consecutive patients with cT3 low and mid rectal
cancer with ypCR after neoadjuvant CRT, treated and
TABLE 1 Clinicopathologic and treatment characteristics according to complete pathologic response (ypCR) in 139 cT3 rectal cancer patients
treated with neoadjuvant chemoradiation
Variable Total, n (%) ypCR, n (%) No ypCR, n (%) P-value
Sex
Female 46 (33.1) 15 (35.7) 31 (32.0)
Male 93 (66.9) 27 (64.3) 66 (68.0) 0.67
Age (years)
Median (range) 62 (25–87) 65 (40–85) 62 (25–87) 0.16
Distance from anal verge (cm)
B5 86 (61.9) 29 (69.1) 57 (58.8)
[5 53 (38.1) 13 (30.9) 40 (41.2) 0.25
Clinical lymph node status
cN0 72 (51.8) 22 (52.4) 50 (51.6)
cN1 67 (48.2) 20 (47.6) 47 (48.4) 0.93
Dose of radiotherapy delivered
45 Gy/25 41 (29.5) 13 (30.9) 28 (28.9)
50.4 Gy/28 98 (70.5) 29 (69.1) 69 (71.1) 0.80
Type of chemotherapy
5-FU/LV 39 (28.1) 13 (30.9) 26 (26.8)
5-FU c.i. ? geﬁtinib 21 (15.1) 7 (16.7) 14 (14.4)
CAPE 26 (18.7) 7 (16.7) 19 (19.6)
Raltitrexed 32 (23.0) 7 (16.7) 25 (25.8)
CAPE ? OXA 21 (15.1) 8 (19.0) 13 (13.4) 0.72
Type of surgery
LE 29 (20.9) 17 (40.5) 12 (12.4)
TME (LAR or APR) 110 (79.1) 25 (59.5) 85 (87.6) 0.0002
Pathologic lymph node status
ypN0 83 (75.4) 22 (88.0) 61 (71.8) 0.097
ypN1–2 27 (24.6) 3 (12.0) 24 (28.2)
IORT
No 98 (70.5) 31 (73.8) 67 (69.1)
Yes 30 (29.5) 11 (26.2) 30 (30.9) 0.32
Adjuvant chemotherapy
No 100 (71.9) 37 (88.1) 63 (64.9)
Yes 39 (28.1) 5 (11.9) 34 (35.1) 0.006
5-FU 5-ﬂuorouracil, LV leucovorin, c.i. continuous infusion, CAPE capecitabine, OXA oxaliplatinum, LE full-thickness local excision, TME total
mesorectal excision, LAR low anterior resection, APR abdominal perineal resection, IORT intraoperative radiotherapy
Long-Term Outcome of T3 Rectal Cancer with ypCR 3689TABLE 2 Clinicopathologic and treatment characteristics according to type of surgery in 42 cT3 rectal cancer patients with complete path-
ologic response (ypCR) after neoadjuvant chemoradiation
Variable Total, n (%) TME (n = 25), n (%) LE (n = 17), n (%) P-value
Sex
Female 15 (35.7) 8 (32.0) 7 (41.2)
Male 27 (64.3) 17 (68.0) 10 (58.8) 0.54
Age (years)
Median (range) 66 (43–86) 61 (43–80) 67 (46–86) 0.11
Distance from anal verge (cm)
B5 29 (69.1) 12 (48.0) 17 (100)
[5 13 (30.9) 13 (52.0) 0 (0) 0.0003
Clinical lymph node status
cN0 22 (52.4) 10 (40.0) 12 (70.6)
cN1 20 (47.6) 15 (60.0) 5 (29.4) 0.051
Dose of radiotherapy delivered
45 Gy /25 13 (30.9) 6 (24.0) 7 (41.2.)
50.4 Gy /28 29 (69.1) 19 (76.0) 10 (58.8) 0.24
Type of chemotherapy
5-FU/LV 13 (30.9) 6 (24.0) 7 (41.2)
5-FU c.i. ? geﬁtinib 7 (16.7) 5 (20.0) 2 (11.8)
CAPE 7 (16.7) 3 (12.0) 4 (23.5) 0.38
Raltitrexed 7 (16.7) 6 (24.0) 1 (5.9)
CAPE ? OXA 8 (19.0) 5 (20.0) 3 (17.6)
Adjuvant chemotherapy
No 37 (88.1) 22 (88.0) 15 (88.2)
Yes 5 (11.9) 3 (12.0) 2 (11.8) 0.98
TME total mesorectal excision, LE full-thickness local excision, 5-FU 5-ﬂuorouracil, LV leucovorin, c.i. continuous infusion, CAPE capecitabine,
OXA oxaliplatinum, IORT intraoperative radiotherapy
FIG. 1 Kaplan-Meier estimates for disease-speciﬁc survival accord-
ing to complete pathologic response (ypCR) to neoadjuvant
chemoradiation in 139 cT3 rectal cancer patients
FIG. 2 Kaplan-Meier estimates for disease-speciﬁc survival accord-
ing to type of surgical treatment [total mesorectal excision (TME)
surgery vs. full-thickness local excision (LE)] in 42 cT3 rectal cancer
patients with complete pathologic response (ypCR) to neoadjuvant
chemoradiation
3690 C. Belluco et al.prospectively followed up at a single institution during a
12-year period. At pathologic examination of the surgical
specimen, ypCR was observed in 30.2% of the cases. In an
updated analysis on a total of 4,732 rectal cancer patients
treated by preoperative CRT in 81 prospective arms from
phase II and III trials, Sanghera et al.
6 have recently
reported a ypCR rate of 14.8%, varying from 0 to 43% in
the different arms. In their study, factors associated with
ypCR were the use of two drugs, c.i. 5-FU administration,
and RT dose of[45 Gy. These ﬁndings could account for
the relatively high ypCR rate observed by us because 71%
of our patients received 50.4 Gy; in addition, c.i. 5-FU and
two drugs regimens were provided to a large number of our
patients.
Our retrospective survival analysis indicates that
patients with ypCR have statistically signiﬁcantly better
oncologic outcomes than those without ypCR, and that in
patients with ypCR, the risk of developing local recurrence
and distant metastasis during follow-up is considerably
lower, with 5-year DMFS and LRFS of 92.5 and 94.9%,
respectively. Our results are consistent with data reported
by others. Maas et al.
7 in a recent pooled analysis of data
from 3,105 locally advanced rectal cancer cases treated by
preoperative CRT, reported that ypCR disease (n = 484)
had signiﬁcantly better results, with 5-year DFS and LRFS
of 83.3 and 97.2%, respectively. De Campos-Lobato
et al.
10 have recently reported that in a series of 238 locally
advanced rectal cancer cases treated by preoperative CRT
during a 10-year period, 5-year OS, DFS, and LRFS were
92.7, 92.4, and 100%, respectively, in the 58 ypCR
patients. Ro ¨del et al.
12 evaluated pathologic tumor response
on surgical specimens of 385 locally advanced rectal can-
cer patients treated within the preoperative CRT arm of the
CAO/ARO/AIO-94 trial and found that ypCR was an
independent prognostic factor for local and distant metas-
tasis. Capirci et al.
9 in an outcome analysis on a pool of 566
patients with locally advanced rectal cancer and ypCR after
preoperative RT with or without chemotherapy, reported 5-
year rates of OS, DSS, and DFS of 90, 94, and 85%,
respectively, with a local recurrence rate of 1.6%. Other
studies have observed better long-term outcome in patients
with primary tumor downstaging (ypT0–2 vs. ypT3–4).
11,38
On the basis of this evidence, it has been postulated that
tumoral ypCR achievement might be indicative of a
prognostically favorable biological tumor proﬁle with less
propensity for local or distant recurrence and improved
survival.
7 Alternatively, signiﬁcantly lower local recur-
rence rate and distant metastasis rate in the subset of
tumors displaying ypCR might be explained by a higher
sensitivity to both radiation and chemotherapy.
In our study, when comparing pre-CRT lymph node
staging and lymph node pathologic status, a trend associ-
ation was observed between ypCR achievement and
mesorectal lymph node downstaging. Moreover, we found
metastatic lymph nodes in 12% of patients with ypCR
compared to 29% in patients with no ypCR. Notably, all
our three patients with ypCR and metastatic mesorectal
lymph nodes were staged as having cN-positive disease
before CRT. Our data are similar to the ﬁgures reported by
Hughes et al.
15 in a study of 143 patients in which the
incidence rate of metastatic mesorectal lymph nodes was
17% in the 23 patients with ypCR versus 35% in patients
with no ypCR. However, other authors have reported lower
incidence rates of metastatic mesorectal lymph nodes in
patients with ypCR. In a study by Coco et al.
13 of 272
rectal cancer patients, the rate of positive nodes in ypCR
cases was 1.8%, while it ranged between 24.1 and 52.0% in
FIG. 3 Kaplan-Meier estimates for disease-speciﬁc survival accord-
ing to complete pathologic response (ypCR) to neoadjuvant
chemoradiation in 29 cT3 rectal cancer patients treated by full-
thickness local excision (LE)
TABLE 3 Multivariate adjusted hazard ratios (HR)
a and 95% CIs in
patients with complete pathological response (ypCR)
Outcome ypCR (n = 97) vs.
no ypCR (n = 42),
HR (95% CI)
P-value
OS 0.26 (0.09–0.80) 0.0185
DSS 0.08 (0.01–0.63) 0.0164
DFS 0.23 (0.09–0.61) 0.0034
DMFS 0.30 (0.10–0.92) 0.0353
LRFS 0.15 (0.03–0.70) 0.0155
HR hazard ratio, CI conﬁdence interval, OS overall survival, DSS
disease-speciﬁc survival, DFS disease-free survival, DMFS distant
metastasis–free survival, LRFS local recurrence–free survival
a Adjusted by pre-chemoradiation clinical lymph node status (cN0
vs. cN1) and type of surgery (total mesorectal excision vs. full-
thickness local excision)
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17 in a study of 235
patients reported positive nodes rate of 2% in ypT0 cases
versus 38% in ypT3 cases. Read et al.
39 in 644 patients
treated by preoperative RT or CRT, reported metastatic
lymph nodes in 1 (2%) of 42 ypT0 patients and in 158
(36%) of 602 ypT1–4 patients. Similarly, Guillem et al.
40
in a series of 188 cT3N rectal cancers treated by CRT and
TME, found that metastatic mesorectal lymph nodes inci-
dence increased from 3% in ypT0 to 36% in ypT3–4.
In our study, subset survival analysis in patients with
ypCR demonstrated no outcome differences in the group of
patients treated by LE compared to patients treated by TME.
In the 17 ypCR patients treated by LE, 5-year DSS, DMFS,
and LRFS were 100, 87.4, and 92.9%, respectively. These
ﬁndings conﬁrm previous data reported by Bonnen et al.
23
from M. D. Anderson Cancer Center, who found no 5-year
OS,DFS,andLRFSdifferencesincT3rectalcancerpatients
comparing 26 patients treated by LE (ypCR = 54%) with
169 patients treated by TME (ypCR = 22%). Callender
et al., from the same institution, have recently compared
outcomes in a larger cohort of patients and reevaluated the
original patients after longer follow-up: 47 patients under-
went LE (ypCR = 49%) and 473 patients underwent TME
(ypCR = 23%). There was no statistically signiﬁcant dif-
ference between the 10-year actuarial local recurrence rate
for the LE group versus the TME group (10.6 and 7.6%,
respectively), and no signiﬁcant difference in OS, DSS, and
DFS between groups.
19 Kundel et al.
16 in 320 locally
advanced rectal cancers, compared ypCR patients who had
LE (n = 14) with those who underwent TME (n = 37).
With a median follow-up of 48 months, no patients in LE
groupexperiencedrecurrence,versus4inTMEgroup,while
OS, DFS, and LRFS were similar in both groups. Guerrieri
et al.
20 reported that in 61 cT3 rectal cancer treated by CRT
and transanal endoscopic microsurgery, long-term local and
distant metastasis failure probability were both 0% in 9
ypCR patients, compared to 5 and 4% in no-ypCR patients.
Nair et al.
21 in 44 cT2–3 rectal cancers treated by CRT and
LEreportedthatlocalrecurrenceanddistantmetastasisrates
were both 4% in the 25 ypCR patients, compared to both
16% in no-ypCR patients. Finally, Habr-Gama et al.
27
reported long-term outcome results of their experience
comparing operative and nonoperative treatment in 265
patients with rectal adenocarcinoma (mostly cT3) treated by
CRT. Patients with incomplete clinical response were
referred to TME surgery. Patients with incomplete clinical
response treated by surgery resulting in ypCR were com-
pared to patients with complete clinical response treated by
nonoperative treatment. Five-year OS and DFS were 88 and
83%, respectively, in the resection group and 100 and 92%
in the observation group.
In conclusion, within the limitations of retrospective
analysis, our data conﬁrm the existing evidence indicating
that patients with ypCR rectal cancer after preoperative
CRT have a favorable long-term outcome, with a low risk
of local recurrence and distant metastasis regardless of the
type of surgical treatment. Such patients appear to be good
candidates for organ-preserving strategies to be explored in
clinical studies. On the other hand, the poor outcome of no-
ypCR patients treated by LE strongly indicates that con-
servative surgical treatment should be avoided in this
subset of patients. In parallel, new functional imaging
modalities and molecular factors that are predictive of
response to treatment should be investigated because they
might be used to select the best treatment and to develop
strategies aimed at enhancing the effectiveness of CRT.
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